1 Min Read
Oct 19 (Reuters) - Immune Design Corp
* Immune design announces G100’S receipt of orphan drug designation by the EMA for the treatment of follicular non-Hodgkin’s lymphoma Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.